Sandu Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Sandu Pharmaceuticals' es Umesh Sandu , nombrado en Jun 2018, tiene una permanencia de 5.83 años. compensación anual total es ₹8.93M, compuesta por 94.6% salario y 5.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 14.37% de las acciones de la empresa, por valor de ₹85.99M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 3.3 años, respectivamente.

Información clave

Umesh Sandu

Chief Executive Officer (CEO)

₹8.9m

Compensación total

Porcentaje del salario del CEO	94.6%
Permanencia del CEO	5.9yrs
Participación del CEO	14.4%
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Umesh Sandu en comparación con los beneficios de Sandu Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹11m
Sep 30 2023	n/a	n/a	₹14m
Jun 30 2023	n/a	n/a	₹15m
Mar 31 2023	₹9m	₹8m	₹15m
Dec 31 2022	n/a	n/a	₹15m
Sep 30 2022	n/a	n/a	₹15m
Jun 30 2022	n/a	n/a	₹16m
Mar 31 2022	₹7m	₹7m	₹16m
Dec 31 2021	n/a	n/a	₹17m
Sep 30 2021	n/a	n/a	₹15m
Jun 30 2021	n/a	n/a	₹15m
Mar 31 2021	₹4m	₹3m	₹11m
Dec 31 2020	n/a	n/a	₹7m
Sep 30 2020	n/a	n/a	₹6m
Jun 30 2020	n/a	n/a	₹4m
Mar 31 2020	₹4m	₹3m	₹7m
Dec 31 2019	n/a	n/a	₹7m
Sep 30 2019	n/a	n/a	₹6m
Jun 30 2019	n/a	n/a	₹7m
Mar 31 2019	₹4m	₹3m	₹7m
Dec 31 2018	n/a	n/a	₹9m
Sep 30 2018	n/a	n/a	₹14m
Jun 30 2018	n/a	n/a	₹14m
Mar 31 2018	₹3m	₹3m	₹6m

Compensación vs. Mercado: La compensación total de Umesh($USD107.17K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD39.52K).

Compensación vs. Ingresos: La compensación de Umesh ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Umesh Sandu (56 yo)

5.9yrs

Permanencia

₹8,927,520

Compensación

Mr. Umesh Bhaskar Sandu serves as the Managing Director and Executive Director of Sandu Pharmaceuticals Limited since June 2, 2018 and served as its Company Secretary.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Umesh Sandu	MD & Executive Director	5.9yrs	₹8.93m	14.37% ₹ 85.9m
Pratika Mhambray	Compliance Officer & Company Secretary	9.1yrs	₹773.00k	sin datos
Vijay Kajrekar	Chief Financial Officer	less than a year	sin datos	sin datos

5.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 524703 es experimentado (5.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Umesh Sandu	MD & Executive Director	5.9yrs	₹8.93m	14.37% ₹ 85.9m
Shashank Sandu	Non-Executive Director	12.9yrs	₹51.00k	14.17% ₹ 84.7m
Shubhada Sandu	Non-Executive Director	9.1yrs	₹30.00k	0.10% ₹ 618.5k
Ajit Kantak	Non-Executive Independent Director	less than a year	sin datos	sin datos
Balaram Vishwanathan	Non Executive Independent Chairman	less than a year	sin datos	sin datos

5.9yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 524703 se considera experimentada (3.3 años de antigüedad promedio).

Sandu Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: ₹0.21 (vs ₹0.51 in 3Q 2023)

Sandu Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.57 (vs ₹0.64 in 2Q 2023)

Investor sentiment improves as stock rises 19%

Sandu Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 13, 2023

Investor sentiment improves as stock rises 23%

Upcoming dividend of ₹0.75 per share at 1.1% yield

Full year 2023 earnings released: EPS: ₹1.62 (vs ₹1.99 in FY 2022)

New minor risk - Financial data availability

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Sandu Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: EPS: ₹0.51 (vs ₹0.57 in 3Q 2022)

Sandu Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: ₹0.64 (vs ₹0.57 in 2Q 2022)

Insufficient new directors

Sandu Pharmaceuticals Limited to Report Q2, 2022 Results on Nov 14, 2022

Sandu Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.75 per share

Sandu Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended 31 March 2022

Sandu Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: EPS: ₹1.99 (vs ₹1.54 in FY 2021)

Sandu Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sandu Pharmaceuticals Limited Approves Appointment of K Vinay Kumar as Chairman

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.57 (vs ₹0.56 in 2Q 2021)

Insufficient new directors

Sandu Pharmaceuticals Limited Resumed Manufacturing Operation to the Extent of 100% at Pilerne Industrial Estate, Goa

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Announces Closure of Goa Factory

Investor sentiment improved over the past week

Sandu Pharmaceuticals Limited announced that it expects to receive INR 13.319198 million in funding from Akshath Finvest & Properties Pvt. Ltd., Neelambar leasing and Finvest Private, Sanbro Marketting Services Private Limited

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹0.41 (vs ₹0.22 in 3Q 2020)

Sandu Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day high: ₹40.30

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: ₹32.65

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹0.56

Sandu Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 13, 2020

Market pulls back on stock over the past week

New 90-day high: ₹25.85

First quarter earnings released

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 14, 2020

Sandu Pharmaceuticals Limited announced that it expects to receive INR 9.595 million in funding from Akshath Finvest & Properties Pvt. Ltd., and other investors

New 90-day high - ₹22.75

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 31, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad